GNW News: Global Data from ROSETTA Lung-02 Study: Encouraging Efficacy for BioNTech and Bristol Myers Squibb’s Bispecific PD-L1xVEGF-A Immunomodulator…

^* First bispecific PD-(L)1xVEGF immunomodulator candidate to which global

Data with encouraging efficacy in combination with chemotherapy in the

First-line treatment of non-small cell lung cancer via various

PD-L1 expression levels and subtypes are presented; Data

underscore the potential of Pumitamig to become a new standard of care

to establish the therapy of lung cancer

* Pumitamig in combination with chemotherapy showed in the

First-line treatment of non-small cell lung cancer in both

doses examined demonstrated robust and consistent anti-tumor activity

with higher confirmed objective response rates of 63.6% in non-

squamous and 72.7% in squamous subtypes in the

lower dosage

* Pumitamig is being evaluated as part of a comprehensive global Phase 3 clinical trial

development program for non-small cell lung cancer,

including the actively recruiting, approval-relevant phase 3 part of the

ROSETTA Lung-02 study and two additional global phase 3 clinical studies

MAINZ, Germany and PRINCETON, USA, May 30, 2026 – BioNTech SE

(https://www.biontech.com/de/de/home.html) (Nasdaq: BNTX,?BioNTech”) and

Bristol Myers Squibb Company (https://www.bms.com/de) (NYSE: BMY,?BMS”) announced

today interim results from the global phase 2/3 study ROSETTA-Lung-02

(NCT06712316 (https://clinicaltrials.gov/study/NCT06712316)). In the

Study will evaluate the PD-L1xVEGF-A immunomodulator candidate Pumitamig (also known as

BNT327 or BMS-986545) in combination with chemotherapy in previously untreated

Patients with advanced non-small cell lung cancer

(non-small cell lung cancer, “NSCLC”).

The data showed encouraging anti-tumor activity with high response rates

across all PD-L1 expression levels (Tumor Proportion Score, TPS °

Selected leverage products on BioNTech (ADRs)

With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on BioNTech (ADRs)

The leverage must be between 2 and 20

Advertising